High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients:: report of five cases

被引:14
作者
Schönholzer, C
Keusch, G
Nigg, L
Robert, D
Wauters, JP
机构
[1] Osped Civ, Lugano, Switzerland
[2] Stadtspital Waid, Zurich, Switzerland
[3] Univ Zurich, Zurich, Switzerland
[4] Hop Providence, Neuchatel, Switzerland
[5] Univ Hosp Bern, CH-3010 Bern, Switzerland
关键词
anti-erythropoietin antibodies; chronic dialysis; chronic kidney failure; end-stage renal disease; erythropoietin; pure red-cell aplasia; renal anaemia;
D O I
10.1093/ndt/gfh307
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Pure red-cell aplasia (PRCA) after erythropoietin (Epo) administration due to the appearance of neutralizing anti-Epo antibodies has been reported in over 200 cases between 1998 and 2002. However, large intercountry disparities were observed in the occurrence of this syndrome. Methods. On behalf of the Swiss Society of Nephrology, a survey was conducted in all the dialysis units of Switzerland in order to collect information on the occurrence, diagnostic and evolution data of the cases observed. A questionnaire was send to the nephrologists in charge of each of the 69 dialysis units in January 2003. The clinical and biological data of the suspected cases were analysed and compared with the data provided to health authorities and pharmaceutical companies. Results. A total of five cases were identified as true PRCA with demonstrated positive anti-Epo antibodies. They occurred between November 1998 and February 2002, were all treated by haemodialysis and had received Epo subcutaneously. The median appearance time of refractory anaemia after Epo initiation was 10 months (range: 7-54 months). Two cases had been treated exclusively with epoietin-alpha, one solely with epoietin-beta and the two others with a combination of both. With five cases out of a total of about 2500 dialysis patients and 2300 Epo-treated dialysis patients or an exposure rate to Epo of 9900 dialysis patient-years during a 4.3 year period, this prevalence is among the highest of those reported in European countries. Conclusions. The prevalence of PRCA after Epo administration in dialysis patients appears particularly high in Switzerland. Among the potential explanations, the most plausible are the high percentage of dialysis patients treated with Epo, the almost exclusive subcutaneous administration, the larger market distribution of the epoietin-alpha brand, the eventual disruption of the cold chain and the setting-up of a systematic national survey.
引用
收藏
页码:2121 / 2125
页数:5
相关论文
共 15 条
[1]  
BERGREM H, 1993, ERYTHROPOIETIN MOL P, P266
[2]   Drug-induced autoimmune red-cell aplasia. [J].
Bunn, HF .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :522-523
[3]   Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].
Casadevall, N ;
Nataf, J ;
Viron, B ;
Kolta, A ;
Kiladjian, J ;
Martin-Dupont, P ;
Michaud, P ;
Papo, T ;
Ugo, V ;
Teyssandier, I ;
Varet, B ;
Mayeux, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :469-475
[4]   Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin [J].
Casadevall, N .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 :37-41
[5]   Pure red-cell aplasia due to anti-erythropoietin antibodies [J].
Eckardt, KU ;
Casadevall, N .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (05) :865-869
[6]   ISOLATION AND CHARACTERIZATION OF GENOMIC AND CDNA CLONES OF HUMAN ERYTHROPOIETIN [J].
JACOBS, K ;
SHOEMAKER, C ;
RUDERSDORF, R ;
NEILL, SD ;
KAUFMAN, RJ ;
MUFSON, A ;
SEEHRA, J ;
JONES, SS ;
HEWICK, R ;
FRITSCH, EF ;
KAWAKITA, M ;
SHIMIZU, T ;
MIYAKE, T .
NATURE, 1985, 313 (6005) :806-810
[7]   CLONING AND EXPRESSION OF THE HUMAN ERYTHROPOIETIN GENE [J].
LIN, FK ;
SUGGS, S ;
LIN, CH ;
BROWNE, JK ;
SMALLING, R ;
EGRIE, JC ;
CHEN, KK ;
FOX, GM ;
MARTIN, F ;
STABINSKY, Z ;
BADRAWI, SM ;
LAI, PH ;
GOLDWASSER, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (22) :7580-7584
[8]   Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia:: where are we now and where do we go from here? [J].
Locatelli, F ;
Aljama, P ;
Barany, P ;
Canaud, B ;
Carrera, F ;
Eckardt, KU ;
Macdougall, IC ;
Macleod, A ;
Hörl, WH ;
Wiecek, A ;
Cameron, S .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (02) :288-293
[9]  
MARMIER G, 2003, SCHWEIZ MED FORUM, V45, P1083
[10]  
NIGG L, UNPUB THERAPY RESIST